GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

M. Rubenstein, M. Shaw, P. Targonski, C. F. McKiel, A. Dubin, P. Guinan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

Original languageEnglish (US)
Pages (from-to)309-312
Number of pages4
JournalUrological Research
Volume19
Issue number5
DOIs
StatePublished - Sep 1991
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Intercellular Signaling Peptides and Proteins
Phenotype
Androgens
Testosterone
Neoplasms
Macrophage Colony-Stimulating Factor
Growth Factor Receptors
Prostatic Neoplasms
Adenocarcinoma
Bone Marrow
Hormones
Drug Therapy
Therapeutics

Keywords

  • Differentiation
  • Dunning tumor
  • GM-CSF
  • Growth factors
  • Prostate
  • Therapy

ASJC Scopus subject areas

  • Urology

Cite this

Rubenstein, M., Shaw, M., Targonski, P., McKiel, C. F., Dubin, A., & Guinan, P. (1991). GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor. Urological Research, 19(5), 309-312. https://doi.org/10.1007/BF00299066

GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor. / Rubenstein, M.; Shaw, M.; Targonski, P.; McKiel, C. F.; Dubin, A.; Guinan, P.

In: Urological Research, Vol. 19, No. 5, 09.1991, p. 309-312.

Research output: Contribution to journalArticle

Rubenstein, M, Shaw, M, Targonski, P, McKiel, CF, Dubin, A & Guinan, P 1991, 'GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor', Urological Research, vol. 19, no. 5, pp. 309-312. https://doi.org/10.1007/BF00299066
Rubenstein, M. ; Shaw, M. ; Targonski, P. ; McKiel, C. F. ; Dubin, A. ; Guinan, P. / GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor. In: Urological Research. 1991 ; Vol. 19, No. 5. pp. 309-312.
@article{c559713779404537a5a804758d013c47,
title = "GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor",
abstract = "GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.",
keywords = "Differentiation, Dunning tumor, GM-CSF, Growth factors, Prostate, Therapy",
author = "M. Rubenstein and M. Shaw and P. Targonski and McKiel, {C. F.} and A. Dubin and P. Guinan",
year = "1991",
month = "9",
doi = "10.1007/BF00299066",
language = "English (US)",
volume = "19",
pages = "309--312",
journal = "Urolithiasis",
issn = "2194-7228",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumor

AU - Rubenstein, M.

AU - Shaw, M.

AU - Targonski, P.

AU - McKiel, C. F.

AU - Dubin, A.

AU - Guinan, P.

PY - 1991/9

Y1 - 1991/9

N2 - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

AB - GM-CSF (granulocyte-macrophage-derived colony-stimulating factor) is a differentiation agent that stimulates bone marrow activity in patients receiving chemotherapy. GM-CSF (1 μg/ml daily for 10 days), administered intralesionally, was evaluated to determine whether it would restore a more differentiated phenotype to an anaplastic, rapidly growing, hormone-independent variant (R3327 MAT-LyLu) of the Dunning prostatic adenocarcinoma. Immunohistology was used to quantitate the expression of epithelial growth factor receptors (rEGF) and the tissue testosterone content. GM-CSF therapy significantly (P<0.05) restored rEGF expression and tissue testosterone to levels associated with better differentiated, slower growing, androgen-dependent Dunning variants (R3327 H and G). GM-CSF may have a role in treatment of prostatic cancers by promoting androgen and epithelial growth factor regulation.

KW - Differentiation

KW - Dunning tumor

KW - GM-CSF

KW - Growth factors

KW - Prostate

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0025787553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025787553&partnerID=8YFLogxK

U2 - 10.1007/BF00299066

DO - 10.1007/BF00299066

M3 - Article

C2 - 1949430

AN - SCOPUS:0025787553

VL - 19

SP - 309

EP - 312

JO - Urolithiasis

JF - Urolithiasis

SN - 2194-7228

IS - 5

ER -